Global Blood Products Market Share Grows Steadily at a CAGR of 4.50%

Introduction

The global blood products market is experiencing steady growth due to several key drivers. A major factor is the increasing number of surgical procedures and trauma incidents worldwide, which has led to a higher demand for blood transfusions essential for patient care and recovery. In addition, government-led efforts to encourage voluntary blood donations and enforce stricter safety regulations have improved both the supply and quality of safe blood products, contributing to market growth.

The aging global population also plays a significant role, as elderly individuals are more likely to need transfusion treatments for chronic conditions such as anemia and heart disease. Furthermore, the expanding use of plasma-derived therapies for managing immune system disorders and neurological conditions is broadening the market landscape. These therapies are gaining wider acceptance due to their proven effectiveness in treating complex medical issues. Altogether, these trends are driving a consistent demand for blood products, highlighting their essential function in modern healthcare.

Market Dynamics

The growing prevalence of blood-related disorders drives the global market

The rising incidence of blood-related conditions such as hemophilia, anemia, and leukemia is a major factor driving growth in the global blood products market. These disorders often necessitate frequent blood transfusions and the use of specific blood components, thereby increasing overall demand.

• Data from the World Federation of Hemophilia indicates that over 347,000 individuals were diagnosed with hemophilia globally in 2023, marking a significant rise.
• Additionally, a recent publication in The Lancetreveals that anemia affects around 24.3% of the global population—approximately 1.92 billion people.
• Moreover, the Leukemia & Lymphoma Society noted that the United States saw more than 60,000 new leukemia cases in 2023 alone.

These concerning figures highlight the expanding global patient base that relies heavily on blood products and associated treatments.

Development of synthetic blood and alternatives creates tremendous opportunities

The emergence of synthetic blood and its alternatives presents a groundbreaking solution to ongoing shortages in the global blood products market. Traditional donation-based systems are hindered by challenges such as limited donor availability, potential contamination, and short shelf life. Synthetic blood, which replicates the oxygen-transporting function of red blood cells, shows significant potential for use in emergency care, military medicine, and remote or underserved areas.

• For example, in November 2024, researchers from the University of Nottingham developed a technique using a patient's own blood combined with synthetic peptides to create ‘biocooperative’ materials. These materials demonstrated the ability to repair bone in animal studies, highlighting the potential for customized regenerative therapies.

These advancements not only fulfill critical clinical demands but also pave the way for personalized medical treatments, boosting the use of synthetic blood in both therapeutic and surgical contexts.

Regional Analysis

The North American blood products market is experiencing steady growth driven by advanced healthcare infrastructure and rising demand for plasma-derived therapies. The U.S. leads with significant investments in blood safety technologies, such as pathogen reduction systems implemented by major blood centers like the American Red Cross. Increasing cases of chronic conditions like hemophilia and immune disorders fuel demand for factor concentrates and immunoglobulins. Canada is focusing on expanding voluntary blood donation programs to address shortages and improve supply chain resilience.

Additionally, North America is witnessing growth in innovative treatments, including gene therapies that use blood components as delivery vectors. The presence of key players like Grifols and CSL Plasma, investing in large-scale plasma collection centers, further strengthens the region’s market position. However, regulatory complexities and high operational costs remain challenges, encouraging companies to adopt automation and digital tools for better blood product management and compliance.

Key Highlights

• The global blood products market size was valued at USD 37.12 billion in 2024 and is estimated to grow from USD 38.79 billion in 2025 to reach USD 55.16 billion by 2033, growing at a CAGR of 4.50% during the forecast period (2025–2033).
• By product type, the global blood products market is segmented into whole blood, red blood cells (RBCs), white blood cells, platelets, plasma, and others.
• By application, the market includes anemia, hemophilia, surgical procedures, trauma and accident care, cancer treatment, immunodeficiency diseases, and others.
• Based on end users, the market is categorized into hospitals, blood banks, diagnostic laboratories, ambulatory surgical centers, and others.
• North America is the highest shareholder in the global market.

Competitive Players

1. CSL Limited
2. Grifols S.A
3. Baxter International Inc.
4. Takeda Pharmaceutical Company Limited
5. Octapharma AG
6. Bio-Rad Laboratories, Inc
7. Haemonetics Corporation
8. LFB Group
9. Macopharma
10. Terumo Corporation
11. others

Recent Developments

• In January 2025, VectorBuilder’s partner, Ucello, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its allogeneic CAR-T cell therapy, UC101, which targets CD19 and is derived from umbilical cord blood. VectorBuilder supported this clinical program by delivering fully customized, end-to-end CDMO solutions.

Segmentation

1. By Product Type
   1. Whole Blood
   2. Red Blood Cells (RBCs)
   3. White Blood Cells
   4. Platelets
   5. Plasma
      1. Fresh Frozen Plasma (FFP)
      2. Immunoglobulins
      3. Albumin
      4. Coagulation Factors
   6. Others
2. By Application
   1. Anemia
   2. Hemophilia
   3. Surgical Procedures
   4. Trauma and Accident Care
   5. Cancer Treatment
   6. Immunodeficiency Diseases
   7. Others
3. By End User
   1. Hospitals
   2. Blood Banks
   3. Diagnostic Laboratories
   4. Ambulatory Surgical Centers
   5. Others
4. By Regions
   1. North America
   2. Europe
   3. Asia-Pacific
   4. Latin America
   5. The Middle East and Africa